New research is pointing to the possibility that genetics, not just environment, plays a pivotal role in the development of Alzheimer's disease, specifically in individuals with dual copies of a gene variant known as APOE4. According to a recent study published in Nature Medicine, these findings could redefine how up to a fifth of Alzheimer's patients are diagnosed and treated.
The study spearheaded by neurologist Reisa Sperling at Mass General Brigham highlights that, for the first time, there's significant evidence directly linking the APOE4 gene variant to an increased likelihood of the disease in carriers. Sperling explained, "Designating this form of Alzheimer's disease means, a group of people who are extremely likely — I won’t say absolutely, but extremely likely — to develop Alzheimer's could be treated earlier." The reshaped understanding could influence the medical community's approach to early diagnosis and quest for novel therapies.
Alzheimer's, often diagnosed in older individuals, has always had a suspected genetic component. However, this study bridges the gap between the already-known rare genetic forms and the more common late-onset Alzheimer's disease. "It links the rare genetic forms of Alzheimer's to what we call sporadic late-onset Alzheimer's disease," Sperling told Harvard Gazette, clarifying the significant jump science has made in understanding the disease pathway.
While it's estimated that about 2 percent of the general population carries two copies of the gene variant, the occurrence of even one copy is relatively common, with variations across different parts of the world. With such wide-reaching implications, the push now, for science is to deepen the understanding of Alzheimer's disease's environmental and lifestyle links. Sperlify commented, "This research really supports both ideas that genetics is a major driver in Alzheimer’s disease, but you can modulate your risk of showing symptoms."
The revelations of this study innovate a more inclusive perspective on the genetics of Alzheimer's disease. Sperling emphasized the importance of expanding this research to include diverse populations, as preliminary evidence indicates some racial and sex differences in the way APOE4 affects amyloid buildup in the brain. "We desperately need to know whether these findings are also true in more ethnic and racially diverse populations," she said, highlighting the need for a comprehensive scope of investigation for better diagnosis and treatments.
For individuals and families grappling with the impact of Alzheimer's, this genetic insight could mean significant changes in the future of treatments and preventive strategies. "This is another tool to be able to find people who have Alzheimer’s disease at an earlier stage and treat them earlier," Sperling remarked, providing a semblance of hope in an area that has long been shadowed by uncertainty and fear.
